<DOC>
	<DOCNO>NCT00019539</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance . PURPOSE : Randomized phase II trial determine effectiveness monoclonal antibody therapy treat patient advanced kidney cancer surgically remove .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect monoclonal antibody VEGF time progression , angiogenesis , overall survival patient unresectable advanced renal cell cancer . II . Evaluate serum antibody level biologically active vascular endothelial growth factor level plasma patient treated regimen . III . Evaluate toxicity regimen patient . PROTOCOL OUTLINE : This randomize study . Patients stratify prior interleukin-2 therapy ( yes v ) . Patients randomize receive either placebo one two dos monoclonal antibody VEGF . Following initial load dose , patient receive one dose study drug intravenously every 2 week 2 year absence disease progression . Patients give placebo experience disease progression offer monoclonal antibody VEGF thalidomide contraindication . PROJECTED ACCRUAL : A total 150 patient accrue study 2 year .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically proven unresectable advanced renal cell cancer Measurable disease Must receive suitable candidate interleukin2 therapy No papillary collect duct renal cell cancer No CNS metastases Prior/Concurrent Therapy Biologic therapy : See Disease Characteristics No prior thalidomide At least 4 week since prior biologic therapy No concurrent biologic therapy Chemotherapy : At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 4 week since prior endocrine therapy No concurrent corticosteroid therapy Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Patient Characteristics Age : 18 Performance status : ECOG 02 Life expectancy : At least 6 month Hematopoietic : WBC least 1,000/mm3 Platelet count least 75,000/mm3 No coagulation disorder , active bleeding , wound heal problem Hepatic : Total bilirubin great 2.0 mg/dL ( patient Gilbert 's disease , direct bilirubin le 0.5 mg/dL ) SGOT SGPT great 3 time normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No coronary artery disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No clinically evident preexist peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2004</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>kidney tumor</keyword>
	<keyword>kidney/urinary cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>renal cell cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>stage , renal cell cancer</keyword>
</DOC>